CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 21 enrolled
Drug / intervention
TOBRADEX Ophthalmic Suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00695435
NCT00695435Phase 1Completed
CompareCT.gov

Evaluation of Tobramycin Tear Concentrations of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension Versus TOBREX® Ophthalmic Solution in Normal Volunteers

Alcon Research·interventional·Posted Jun 11, 2008·Updated Mar 2, 2010

In Brief

A Phase 1 clinical trial evaluating TOBRADEX Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension, and 1 other intervention for Dry Eye. Completed, enrolled 21 participants across 1 site.

Detailed Summary

To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 11, 2008
Enrollment StartJun 1, 2008
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 18.1 years ago

Interventions

TOBRADEX Ophthalmic Suspensiondrug

TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline

Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspensiondrug

Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline

TOBREX Ophthalmic Solutiondrug

TOBREX Ophthalmic Solution 1 drop each eye at baseline